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Human acid sphingomyelinase structures provide
insight to molecular basis of Niemann–Pick disease
Yan-Feng Zhou1,w, Matthew C. Metcalf2, Scott C. Garman2, Tim Edmunds1, Huawei Qiu1 & Ronnie R. Wei1

Acid sphingomyelinase (ASM) hydrolyzes sphingomyelin to ceramide and phosphocholine,
essential components of myelin in neurons. Genetic alterations in ASM lead to ASM
deﬁciency (ASMD) and have been linked to Niemann–Pick disease types A and B. Olipudase
alfa, a recombinant form of human ASM, is being developed as enzyme replacement therapy
to treat the non-neurological manifestations of ASMD. Here we present the human ASM
holoenzyme and product bound structures encompassing all of the functional domains. The
catalytic domain has a metallophosphatase fold, and two zinc ions and one reaction product
phosphocholine are identiﬁed in a histidine-rich active site. The structures reveal the
underlying catalytic mechanism, in which two zinc ions activate a water molecule for
nucleophilic attack of the phosphodiester bond. Docking of sphingomyelin provides a model
that allows insight into the selectivity of the enzyme and how the ASM domains collaborate
to complete hydrolysis. Mapping of known mutations provides a basic understanding on
correlations between enzyme dysfunction and phenotypes observed in ASMD patients.
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A

cid sphingomyelinase deﬁciency (ASMD) causes
abnormal accumulation of sphingomyelin in lysosomes,
resulting in the progressive, life-threatening disorder
historically referred to as Niemann–Pick disease types A
(NPD A), presenting with an early-onset neuronopathic
phenotype, and type B (NPD B), the non-neuronopathic form1.
ASMD is a result of mutations in acid sphingomyelinase (ASM,
E.C. 3.1.4.12), which hydrolyzes sphingomyelin to ceramide and
phosphocholine (Fig. 1a)2. Recent studies on this rare disease
illustrate that ASM plays an important role in the ceramidemediated signalling pathway. Recombinant human ASM
expressed from Chinese hamster ovary (CHO) cells is being
developed as enzyme replacement therapy (ERT) for the
non-neurological manifestations of ASMD, and is currently in
the phase 1/2 pediatric trial and phase 2/3 trial for adults3,4.
ASM is highly conserved in animals, from C. elegans to human,
with over 35% protein sequence identities (Supplementary Fig. 1).
Sequence analysis suggests ASM is a multi-domain protein,
including a saposin domain, a proline-rich linker, a metallodependent phosphatase catalytic domain, and an ill-deﬁned
C-terminal domain (Fig. 1b)5. Saposin proteins are sphingolipid
activator proteins that present lipids from membranes to the
active sites of various enzymes in an acidic cellular
compartment6. The saposin domain in ASM is sufﬁcient to
support the hydrolysis of sphingomyelin without external saposin
proteins7,8. In addition, ASM differs from neutral and alkaline
sphingomyelinases in both domain architecture and protein
sequence, with identities o10%.
Previous biochemical characterizations reveal that proper
function of human ASM (UniProt database ID: P17405) requires
zinc ions, multiple post-translational modiﬁcations, and acidic
pH (ref. 5). On the basis of its localization, two forms of ASM
originating from one gene have been reported, an intracellular
lysosomal form and an extracellular secreted form9. Zinc ions are
prerequisites for activity of both forms10. The lysosomal ASM is
preloaded with zinc, while the secreted form requires exogenous
zinc9. Also, human ASM has six potential N-linked glycosylation
sites, and its in vitro activity pH optimum is around 5 (ref. 11).
However, it is not clear how zinc and other physiological factors
are involved in the enzyme function.
Despite its clinical signiﬁcance, limited structural studies on
ASM have been reported that elucidate its substrate selectivity
and enzymatic mechanism. A model of human ASM catalytic
domain has been generated based on a distant homolog, purple
acid phosphatase12. Two recent crystal structures of catalytic
domain of sphingomyelinase phosphodiesterase like 3a
(SMPDL3A), sharing 31% identities to human ASM, are
reported13,14. However, the understanding on ASMD is limited
to the metal-binding site due to the low sequence identities and
absence of the N-terminal saposin domain.
Here we report two crystal structures of recombinant human
ASM and observe how co-factor zinc ions and a product
phosphocholine are coordinated by the enzyme. The multidomain structures, representing two states in the catalytic cycle,
shed light on the mechanism of how natural substrate
sphingomyelin is recognized and degraded. Moreover, currently
reported ASMD mutations in the UniProt database were mapped
onto the structure to build genotype–phenotype correlations with
atomic details.
Results
Overall structure. Full-length human ASM was expressed from
HEK293S N-acetylglucosaminyl transferase I-deﬁcient (Gnt1  )
cells with Man5 type glycans. ASM in cell culture media was
puriﬁed with a monoclonal antibody coupled afﬁnity column,
2

followed by size exclusion column. Puriﬁed protein was crystallized at pH 5.5. The recombinant human ASM being developed
for ERT, olipudase alfa, was also crystallized without any protease
in the crystallization drops. Olipudase alfa was expressed in CHO
cells with complex glycans15. The olipudase alfa crystals diffracted
to around 4 Å at synchrotron (Table 1), and clear glycosylation
and zinc cofactors densities were observed (Supplementary
Fig. 2). Its reﬁned structure was essentially identical to ASM
from HEK cells. The descriptions in this report are focused on
ASM from HEK cells unless speciﬁed.
ASM shares o10% sequence identity to structurally known
homologues. Therefore, the holoenzyme structure was determined using single-wavelength anomalous diffraction (SAD)
from a Pt derivative at 2.43 Å, and the phases was extended to
2.25 Å using a Zn-SAD data set. The ﬁnal model was reﬁned to
Rfree of 0.203 (Table 1). Clear electron density allowed us to build
all residues from W84 to M611 as well as two zinc ions, six
N-linked glycans, and eight disulﬁdes (Fig. 1c). The same residue
range is visible in the olipudase alfa structure, suggesting ASM N
and C termini are inherently disordered and ﬂexible. The
structure includes an N-terminal saposin domain (residues
84–167), a proline-rich linker (168–195), a catalytic metallophosphatase domain (196–538), and a helical C-terminal domain
(539–611) (Fig. 1).
Saposin domain and proline-rich linker. The presence of
saposin domain and proline-rich linker distinguishes ASM from
all the other structurally known proteins. A number of crystal
structures have demonstrated that saposin proteins undergo open
and close conformational changes in response to lipid binding
(Supplementary Fig. 3)16–18. The four helices in ASM saposin
domain were observed in an extended open conformation in
which helices H1 and H2 run nearly antiparallel to H3 and H4
(Fig. 1c). The helices are stabilized by two disulﬁde bonds
connecting the saposin domain N and C termini and a third
disulﬁde between H2 and H3. As a result, helices H3 and H4 form
tight pairwise helical interactions with H1 and H2. The kinked
H3 helix mediates saposin and catalytic domain interactions. In
contrast, the H1 and H4 helices extend away from the catalytic
domain, and there is no direct contact between H4 and catalytic
domain (Fig. 1c). The four ASM saposin helices are amphipathic.
The concave inner surface is hydrophobic and faces towards the
zinc ions in active site, while the convex outer surface is lined
with hydrophilic residues and exposed to solvent.
A 30-residue linker connects the saposin domain to the
catalytic domain (Fig. 1c,f). The structure reveals that this linker
spans 57 Å and covers 1128 Å2 surface of the catalytic domain.
The linker is bent in the middle at position T180, resulting in a
97° kink. The linker can be divided to prolineless N-terminal half
and proline-rich C-terminal half, based on amino-acid features.
In the prolineless half, there is one glycosylation and several
serine residues, but no proline. In contrast, the C-terminal half is
dominated by proline, with one triple and two double proline
motifs (P182KPPPKPPSPPAP). The prolineless half runs along
the a5 and a6 in catalytic domain and is stabilized through
extensive hydrophobic interactions with a5 and a6. The prolinerich half is extended and wraps around loops following a6, b8
and b10 in catalytic domain.
Catalytic domain. The catalytic domain structure shows two
layers of b-sheets, both six-stranded, form the central core, with
dimensions 47 Å  50 Å  53 Å. Six a-helices and the helical
C-terminal domain ﬂank the b-sheets resulting in a four-layer
a/b/b/a sandwich architecture. The catalytic domain starts at b1
in the center of the ﬁrst sheet and ends at b12 at the edge of this
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Figure 1 | Structure of human ASM. (a) Sphingomyelin degradation catalyzed by ASM. (b) Diagram of ASM domains drawn to scale, with yellow saposin,
orange proline-rich linker, and green C-terminal domain. (c) Overall structure of ASM. Glycosylation and disulﬁde bonds are in sticks. Two zinc ions are in
spheres. (d) Topology of ASM. Upward and downward pointing triangles indicate the N to C terminus orientation of b strands. Open and closed circles
indicate upward and downward going helices, respectively. (e) Cross-section illustration of cleft on ASM surface, with zinc and glycans as spheres. Arrow
points to the center of substrate binding cleft. (f) ASM protein sequence with structural features. Disulﬁdes are shown as matched cysteine colors.
Residues that are not visible in the structure are grey. Underlined residues are reported ASMD mutation sites. Catalytic residues are bold and red.
Glycosylated asparagine residues are green.

sheet (Fig. 1d). The topological arrangement suggests catalytic
domain adopts a metallophosphatase fold (SCOP d.159) and
belongs to a calcineurin-like phosphoesterase superfamily in
Pfam database (PF00149). ASM catalytic domain and C-terminal

domain shares high structural similarity to SMPDL3A
(refs 13,14), with identical topology and root mean square
deviation (r.m.s.d.) of 1.4 Å of all Ca atoms. Superimposition of
ASM catalytic domain to pig purple acid phosphatase (PAP, PDB
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Table 1 | Data collection and reﬁnement statistics.
Data collection
X-ray wavelength (Å)
Resolution (Å)
Space group
No. of reﬂections
Cell dimensions
a, b, c (Å)
a, b, g (°)
I/s(I)
Rmerge
Completeness (%)
Redundancy
CC1/2 in highest shell
Phasing and reﬁnement
Phasing ﬁgure of merit
Rwork/Rfree
Monomers per asymmetric unit
Composition per asymmetric unit
Amino acid/sugar
Water/SO4
Zn/Phosphocholine
rmsd
Bond (Å)
Angle (°)
Ramachandran plot
(favoured/allowed/outlier)

Holo ASM
1.2830
43.81–2.25 (2.33–2.25)
P6422
88030

Pt derivative
1.0721
42.33–2.43 (2.52–2.43)
P6422
68691

Phosphocholine
1.5418
31.18–2.50 (2.64–2.50)
P6422
33985

Olipudase alfa
1.2825
45.00–3.65 (3.74–3.65)
I222
118574

132.5, 132.5, 189.8
90.0, 90.0, 120.0
22.9 (1.9)
0.092 (0.732)
99.5 (94.9)
10.3 (5.0)
0.669

132.2, 132.2, 189.3
90.0, 90.0, 120.0
22.1 (2.0)
0.081 (0.735)
99.0 (90.9)
7.3 (4.9)
0.743

131.6, 131.6, 188.6
90.0, 90.0, 120.0
12.6 (3.2)
0.200 (0.822)
99.9 (100.0)
17.3 (13.9)
0.852

191.0, 230.9, 252.3
90.0, 90.0, 90.0
7.44 (0.34)
0.229 (5.35)
98.9 (86.3)
6.9 (5.4)
0.108

—
0.184/0.203
1

0.251

—
0.190/0.222
1

—
0.248/0.254
3

527/14
177/11
2/0

527/13
261/11
2/1

1581/29
0//0
6/0

0.009
0.902
96.4/3.6/0.0

0.018
0.885
95.4/4.6/0.0

0.013
0.931
95.6/4.2/0.2

1

ASM, acid sphingomyelinase; rmsd, root mean square deviation.
Holo ASM and Pt derivative are anomalous data collected at Zn peak and Pt L-III edge, respectively. Phosphocholine data set is non-anomalous. Olipudase Alfa data set is collected at Zn peak. Values in
parentheses are for the highest-resolution shell.

1UTE) and bacteria neutral sphingomyelinase (PDB 2DDR)
shows r.m.s.d. values of 3.1 and 3.9 Å, respectively. The unique
topological arrangement of b9–10 and b10–12 strands makes the
catalytic domains in ASM and SMPDL3A differ from currently
identiﬁed members in metallophosphatase fold and neutral
sphingomyelinases (DNase I-like fold, SCOP d.151)19.
One feature of the ASM metallophosphatase domain is the
long loops following certain b strands and extending toward the
zinc ions (Fig. 2). These loops not only mediate zinc and substrate
binding but also form the interfaces to the proline-rich linker,
saposin and C-terminal domains. H3 helix in saposin domain
forms extensive contacts to b1-a1, b2-a2, b3-a3 and b5-a5 loops
(Fig. 2a,b). The interface between H3 and these loops is 700 Å2
and over 30 Å long. It is worth noting that many ASMD
mutations occur on the interface residues, such as L137P in H3,
P323A on the b3-a3 loop, DF390 and W391G on the b5-a5 loop.
I170 and F171 on proline-rich linker interact with V150 on
saposin H3 and L393 on b5-a5 loop, resulting in a turn towards
the catalytic domain. The proline-rich linker is further stabilized
by hydrophobic interactions between W174, I176, L178 and the
a5 a6 helices (Fig. 2c). Moreover, the 44-residue b1-a1 loop
extends out from the catalytic domain and folds into a small
globular unit next to the H2-H3 turn in saposin domain (Fig. 2b).
The conformation of this long loop is enforced by internal two
pairs of charged interactions, two pairs of disulﬁdes, and
hydrophobic interactions. This loop is also interacting with
b2-a2, b9-b10 and b11-b12 loops.
The catalytic domain shares a 1,632 Å2 interface with the
C-terminal domain (Fig. 2d). The C-terminal domain starts after
b12 in sheet1 and contains four helices, Ha-c, and a 310 at the C
terminus. The b8–9 strands at the edge of sheet2 deeply inserts
into the space between these helices. Moreover, C-terminal
domain contributes to the stabilization of the active site
conformation, especially the b7–b8 loop. It has been reported
4

that DT592 mutation causes severe ASMD in patients20. T592 is
in the middle of Hc helix, which forms extensive interactions with
the catalytic domain (Fig. 2d). Thus, we predict DT592 mutation
has severe inﬂuence on ASM folding.
Zinc binding in the active site. The long loops in the catalytic
domain, together with saposin and C-terminal domains, create a
deep and wide open cleft (Fig. 1c,e). The saposin and C-terminal
domains are on the opposite sides of the catalytic domain. This is
the only large and deep cleft (15 Å  30 Å  10 Å) on ASM. Six
N-linked glycans scatter on the surface and all distribute far away
from this cleft.
Two neighbouring zinc ions are identiﬁed in the center of the
cleft. The presence of zinc was conﬁrmed by an X-ray
ﬂuorescence scan, and strong zinc anomalous signal has been
observed in the data (Supplementary Fig. 4b). The location of zinc
is at the C-terminal end of strands b1, b2, b6 and b7 (Figs 1c and
3a). The two zinc ions are separated by 3.5 Å and referred to as
Zn1 and Zn2. Both zincs have trigonal bipyramidal geometry.
D278 bridges between Zn1 and Zn2 at the axial positions, while
H457 and H459 are in the other axial positions. Two of the
equatorial positions are occupied by N318 and H425 for Zn1 and
D206 and H208 for Zn2. Mutation of H425A or D206A abolishes
ASM activity12, which is consistent with our structure.
The conformations of the axial ligands H457 and H459 are
constrained by side chains from helices in the C-terminal domain
(Fig. 2d).
The precise side-chain arrangement around the metals
facilitates recruitment of a key catalytic water molecule to the
third equatorial position bridging between Zn1 and Zn2. The
presence of this water is conﬁrmed by observation on omit Fo-Fc
map (Supplementary Fig. 4b). The catalytic water is stabilized and
positioned by hydrogen bonds to the main chain carbonyl of
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H457 (Fig. 3a).There is an asymmetric arrangement in which the
carboxylate oxygen of D278 is slightly closer to Zn2 (D-Zn1 2.5 Å,
D-Zn2 1.9 Å), while the catalytic water is closer to Zn1 (Wat-Zn1
1.9 Å, Wat-Zn2 2.6 Å). In contrast, the coordination of this water
in PAP and SMPDL3A is more symmetric (Supplementary
Fig. 5)14.
Phosphocholine binding. To better understand the ASM
catalytic mechanism and how the Zn ions mediate hydrolysis,
we soaked a product phosphocholine into ASM crystal and solved

the structure to 2.5 Å (Table 1). Clear density was observed near
the zinc atoms in the Fo-Fc difference map (Supplementary
Fig. 4c). One phosphocholine was built into the electron density,
with the choline pointing toward the C-terminal domain
(Fig. 3b). The phosphoryl group is tightly coordinated by both
zinc ions and the neighbouring catalytic residues. Oxygen (O1)
on the phosphoryl group replaces the position of the catalytic
water molecule in the holo ASM structure. N318 and H319 on
b3-a3 loop, H208 on b1, and H282 on b2-a2 loop interact with
two oxygen atoms (O2 and O3) on the phosphoryl group.
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Discussion
Sphingomyelin is a key membrane component from bacteria to
human. Understanding of how sphingomyelin is recognized and
hydrolysed by ASM greatly enhances our knowledge of
sphingolipid metabolism and associated human diseases. Due to
low sequence identity, reliable prediction of human ASM
function cannot be made based on structurally known proteins.
The human ASM structures we report here illustrate how the
co-factor zinc ions activate the enzyme and how domain
arrangement contributes to substrate speciﬁcity.
A putative catalytic mechanism can be deduced for ASM, based
on the structures (Fig. 3c). We crystallized two states in the
ASM catalytic cycle, the holoenzyme state, and product
phosphocholine bound state. We propose that ASM catalysis is
an associative general acid–base type reaction.
The active site in ASM deﬁnes a stringent speciﬁcity for zinc
and the phosphate group of sphingomyelin. The two zinc ions are
coordinated by four histidines, two aspartic acids, one asparagine
and the catalytic water molecule. During the substrate recognition, we speculate that two zinc co-factors serve as anchors for the
two phosphate oxygens from sphingomyelin. The water can be
deprotonated to hydroxide, because the two close zinc ions
extract proton away from this water. Following that, the
hydroxide initiates nucleophilic attack on the phosphorus of
sphingomyelin. The arrangement of the active site allows the
phosphate oxygen on the ceramide side to extra a proton from
either H319 or H282 (Fig. 4a). The H282 imidazole ring is
stabilized by p–p stacking interaction with Y488 and polar
interaction to D251 carboxylate group, while the H319 is involved
in water mediated hydrogen bonding. As a result, H319 is a more
energy favoured hydrogen donor in the reaction. We propose the
imidazole ring on H319 donates a proton to the oxyanion of the
ceramide leaving group. It is worth noting that the cleft is open
and solvent accessible, which allows quick exchange of protons on
both H319 and the nucleophile water in the regeneration step.
Consistent with this hypothesis, mutation of H319 to tyrosine
causes severe ASMD21.
The proposed mechanism is further supported by observations
in other di-metal-binding metallophosphatases. Despite o10%
protein sequence identities, ASM shares a conserved catalytic site
and di-metal binding pattern with other metallophosphatases,
such as mammalian purple acid phosphatase (Supplementary
Fig. 5)22. The di-metal bridging water molecule is found at the
active site in this class of catalytic domains/enzymes. In addition,
the phosphate location is also conserved, with the same trigonal
bipyramidal coordination geometry.

a

Most of the sphingolipid degradation enzymes require
activator proteins, like saposins, to present substrates to the
catalytic domain. ASM has its own saposin domain for
sphingomyelin recognition. Our structure provides direct
observation on how saposin and catalytic domain are arranged
for sphingomyelin recognition.
Major sphingomyelin species in biological membranes have
long acyl chains, with three dominant lengths, C-16, C-18, and
C-24 (ref. 23). The substrate binding cleft in ASM is created by
the catalytic domain in the middle, and saposin domain and
C-terminal domain at two opposite sides. Zinc ions and
phosphocholine occupy the center and the C-terminal domain
side of the cleft. The saposin concave surface facing towards the
active site is rich in hydrophobic residues (Fig. 4a) and not highly
charged (Fig. 4b), which can accommodate the hydrophobic
ceramide chains in sphingomyelin. The distance between Zn1 and
the phenyl ring of F138 in H3 is 14 Å, which is close to the 18 Å
length of an extended 16 carbon chain Ahn et al.16 have shown
that hydrophobic chains of a phosphatidylethanolamine are
accommodated within a hydrophobic cavity at the middle of the
kinked H3 helices in saposin B protein (Supplementary Fig. 3c).
Recent crystal structure of saposin A lipoprotein discs and
cryoelectron microscopic study show sapsoin proteins can wrap
around lipids and membrand protein and form lipoprotein-like
nanoparticles18,24. These observations indicate saposin might be
functional as long as it is under open conformation, regardless
its oligomeric states. With limited knowledge of binding between
saposin proteins and lipids, we did docking of C-16
sphingomyelin onto ASM to visualize how the ceramide chains
can be placed between the active site and the saposin domain
(Fig. 4). The saposin is under open conformation in our
structures. Even with the constraints of phosphocholine and the
kinked region in H3 as docking site, the ﬂexible ceramide chains
were placed various positions (Fig. 4b), instead of form a speciﬁc
interaction network with saposin domain. The modelling result
suggests that sphingomyelins can ﬁt well into the cleft on ASM
surface. We propose it undergoes close–open conformational
changes in response to substrate binding like other saposin
proteins. The proline-rich linker could act as a hinge that
switches the saposin domain conformational changes, facilitating
presentation of substrate to the catalytic domain.
The chemical composition of the hydrocarbon chains
allows sphingomyelin to ﬁt better into ASM cleft than other
phospholipids. Oninla et al.25 has found that ASM catalyses
degradation of C18-sphingomyelin 10-fold faster than
dipalmitoyl-phosphatidylcholine, although they share an
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Figure 4 | Docked model of sphingomyelin on ASM. (a) Surface residues around C-16 sphingomyelin. Zinc atoms are shown gold spheres. Sphingomyelin
is coloured as yellow carbon, blue nitrogen, red oxygen and orange phosphorus. (b) Electrostatic potential surface calculated at pH 5.0 with PropKa (ref. 46)
and PDB2PQR (ref. 47). Red and blue surfaces correspond to negative and positive electrostatic potential scaled from  5 kbT to 5 kbT. Three docked
poses were shown on the surface, and the yellow pose was selected and shown in a.
6

NATURE COMMUNICATIONS | 7:13082 | DOI: 10.1038/ncomms13082 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13082

identical phosphocholine head group. Sphingomyelin in nature is
synthesized with two stereo chemical requirements in the
hydrocarbon chain: the double bond in sphingosine is in trans
conﬁguration, and the C2 amine and C3 hydroxyl must have
threo relationship26. We speculate that these are the two key
factors for proper substrate alignment on ASM. First, the amine
at C2 and hydroxyl at C3 positions are good hydrogen-bond
donors (Fig. 1a), while the glycerol backbone in
phosphatidylcholine has fewer hydrogen-bond donors. N325,
E388 and Y488 in ASM are within 7 Å from the zinc ions and in
position for hydrogen bonding with substrate (Fig. 4a), and N325
is highly conserved among different species (Supplementary
Fig. 1). Hydrogen bonding plus charged interactions with zinc
ions together make substrate recognition highly speciﬁc. Second,
naturally existing sphingomyelin is much more saturated than
phosphatidylcholine, which normally contains one or more
double bonds in cis conﬁguration in the middle of the acyl
chains23. The rigidity of the cis double bond causes the acyl chain
to bend and restricts the conformational freedom. As a result, we
predict the recognition and presentation of phosphatidylcholine
and other phospholipids to ASM active site is slower than that of
sphingomyelin.
ASMD is caused by loss of function mutations in ASM. There
are ninety known mutations listed in UniProt database and
summarized in supplementary Table 1. All mutations are covered
in our structure, except D49V located in the signal peptide.

Mapping mutations onto one dimensional (1D) protein sequence
and 3D structure reveals interesting occurrence pattern in human
ASM (Fig. 5). Overall, 82% of the mutations are located in the
catalytic domain, resulting in 21.6% mutation rate in protein
sequence. In contrast, the mutation rates in the saposin, prolinerich linker, and C-terminal domains are no 411% (Fig. 5a).
Those mutations are predicted into two categories according to
their disruptive effects on catalytic activity and protein folding
(Fig. 5b; Supplementary Table 1). First, the catalytic group
includes mutation of residues that are directly or indirectly
involved in zinc binding or phosphocholine binding in the
speciﬁcity pocket. The indirect residues disrupt the folding near
the active site and thus affect catalysis. For direct coordination,
D278A mutation eliminates the coordination to both zinc atoms.
H319Y not only introduces a larger group to the compact active
site but also loses the imidazole group which plays an essential
role in the phosphodiester bond cleavage. H425 points the
imidazole ring towards zinc atoms, and mutation to the larger
arginine completely disrupts zinc coordination. There are many
other mutations that affect the active site indirectly. For example,
the A281T mutation affects H319, and W209R mutation disrupts
the b1 stability and affects D206 and H208, which coordinate
Zn2. Q292 and H319 are involved in a buried hydrogen-bond
network including A281 and Q287. The Q292 amide forms a
3.2 Å hydrogen bond with the H319 carbonyl. The Q292K
mutation brings a longer side chain into this well-deﬁned
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Figure 5 | Mutations mapped on structure. (a) Distribution of mutations on human ASM 1-D sequence. Each point represents one reported mutation in
the UniProt database. Points are coloured according to domains. (b) Distribution of mutations on 3D structure. Ca atoms of mutated residues are shown as
spheres. Activity-related mutations are red, and folding related ones are black. Zinc atoms are gold spheres. (c) Network of R496 with neighbouring
residues in the hydrophobic core between b-sheets. (d) Hydrophobic interactions mediated by L302 between a1 and a2 helices. In c–d, 2Fo-Fc density for
side chains of mutation sites are shown and contoured at 1s.
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hydrogen bonding network and perturbs the catalytic role
of H319.
Among the mutations in the catalytic domain, there are two
clusters in the 3D structure. One is on the tightly folded b1-a1
loop (Fig. 2b). Mutations like A241V, G242R, G245S, introduce
larger side chains and disrupt local folding. The other cluster
spreads onto b4, b5, b5-a5 loop and b6-a6 loop in the protein
sequence. According to the structure, these mutations are in close
proximity to H3 in the saposin domain, a critical location for
binding of sphingomyelin.
The second group of mutations is on residues that are widely
distributed in the structure and distant from the active site. These
mutations destabilize local interaction networks and affect
enzyme stability and folding (Fig. 5b). Most of the residues are
sequestered from solvent (Supplementary Table 1), and some
surface exposed ones are heavily involved in interactions with
neighboring residues in the folded structure. R496L and L302P
mutations are two of the three prevalent mutations in the
Jewish population and cause NPD A. Both R496 and L302 are
highly conserved among species (Supplementary Fig. 1). The
guanidinium group of R496 forms extensive interactions with
neighboring residues, and stabilize the buried core between the
b-sheets (Fig. 5c). L302 is located in the middle of helix a2, and
the local hydrophobic interactions maintain the stability of a1
and a2, which are next to b1 strand in the active site (Fig. 5d). In
addition, mutation to a proline, which often interrupts helical
structures, further decreases the local stability.
Deletion of R608 (DR608) is the most common mutation in
NPD B, and patients with homozygous DR608 mutations have
mild phenotype. R608 is located after the C594-C607 disulﬁde
bond on a 310 helix. Residues after M611 are missing electron
density and presumably disordered. The residues after R608 show
very low sequence identities among ASM from different species
(Supplementary Fig. 1), but a free cysteine at the C-terminal end
is conserved and the length of this region in most species is
around 20 amino acids. Mutation or deletion of the last residue
C629 in human ASM is known to increase ASM activity and the
cysteine is proposed to form direct contacts to active site27. It has
been reported in other metallophosphatase, like PhoD in Bacillus
subtilis, that the C-terminal end folds back to active site to inhibit
enzyme activity28. We predict that deletion of R608 will disturb
the C terminus and affect its activity. In contrast to DR608,
DT592 has been reported as an NPD A mutation. As described
earlier, T592 forms direct contacts with active site. DT592 will
disrupt the interactions between the C-terminal domain and the
catalytic domain, resulting in a perturbed active site and severe
enzyme deﬁciency (Fig. 2d).
Taken together, we predict how individual mutation affect
enzyme folding and function based on the atomic resolution
structure of ASM. This information allows us to better understand gene mutations and ASMD phenotypes in the context of
enzyme folding and catalytic activity. As abovementioned, we
observe consistent correlations between disease severity and a
disruptive effect on the ASM active site or folding. The structural
information could serve as a guide to analyse and predict the
phenotypic outcome in ASMD individuals. The structures
provide us the ability to understand the molecular mechanism
behind diseases. Following tests of theromostability and
enzymatic assay with ASM mutants will help us better reveal
the predicted correlations.
The abovementioned structures open a door for us to decipher
ASM catalytic mechanism and mutations in ASMD patients.
However, many questions remain unanswered. First one will be
how ASM interacts with membrane and reaches sphingomyelin.
ASM in solution is monomeric, and it has not been reported that
ASM needs to dimerize to function. New evidence with different
8

techniques may better reveal the details. Another question is how
ASM is inhibited by the anti-depressants drugs. Model has been
proposed that those tricyclic drugs would insert into membrane
and adjust charges on the surface, which will interfere the
electrostatic adherence of ASM to membrane29. The structure
shown here does not conﬂict with this model. However, these
hydrophobic tricyclic drugs could also potentially bind to the
hydrophobic surface in sapson domain thus prevent saposin–
sphingomyelin interaction. A following co-crystal structure of
ASM or saposin domain with these small molecules would
provide more insights. Moreover, ASM activity is regulated
by different modiﬁcations and physiological partners, such as
phosphorylation on S508 and association with acid
ceramidase30,31. We observe S508 on b10–b11 loop is partially
buried by the proline-rich linker and hydroxyl group is hydrogen
bonded to D501 in our structures. This serine residue is not
phosphorylated and located in a position distant from substrate
binding site. A crystal structure with phosphorylated S508 may
address the question. ASM could also be activated by redox
conditions and possible through the last free cysteine C629
(refs 27,32). We see that most of the disulﬁdes in ASM are solvent
accessible and the C-terminal C629 are exposed and too ﬂexible
to be seen in our structures. The exposure of these residues may
make ASM sensitive to redox conditions.
We present the atomic resolution structures of human ASM
here, with detailed information about zinc and phosphocholine
binding. The structures allow us to interpret zinc activation and
substrate hydrolysis in ASM. In addition, the results provide
insights about how catalytic domain and its neighboring saposin,
proline-rich linker, and C-terminal domains together create a
cleft speciﬁc for sphingomyelin binding. These data also give us
the opportunity to start correlating mutations in patients and
enzyme deﬁciency.
Methods
Protein expression. Codon optimized DNA encoding human ASM (M1 to C629)
was cloned into the NheI and BamHI sites of plasmid pIRES2-EGFP and
conﬁrmed by sequencing. HEK293S Gnt1  cells (ATCC CRL-3022) were
transfected using polyethylenimine33. Single colonies were selected in Dulbecco’s
modiﬁed Eagle’s medium and 5% fetal bovine serum with 1 mg ml  1 G418. Stably
transfected cells were cultured in suspension in Freestyle 293 serum-free medium,
and supernatants were harvested 7 days after expansion.
Olipudase alfa was produced at Sanoﬁ Genzyme27. Human full-length ASM
cDNA was cloned into a dihydrofolate reductase selection vector and stably
expressed in CHO-DXB11 cells (ATCC CRL-9096).
Protein puriﬁcation. HEK293S Gnt1  cell expressed ASM was puriﬁed from the
supernatant using antibody afﬁnity and gel-ﬁltration chromatography. Anti-ASM
monoclonal antibody was coupled to AminoLink Plus resin (Thermo Scientiﬁc,
USA) following the manufacturer’s protocol. ASM supernatant was adjusted to
20 mM Bis-Tris pH 6.0, 0.15 M sodium chloride and 0.1 mM zinc acetate, and
incubated with resin overnight at 4 °C. ASM was eluted with 20 mM sodium citrate
pH 3.0, and neutralized with 0.1 M Bis-Tris pH 6.5. The eluate was further puriﬁed
using Superdex 200 10/300 GL (GE healthcare, USA) in 20 mM Bis-Tris pH 6.0,
0.15 M sodium chloride (Supplementary Fig. 6). Peak fractions were concentrated
to 20 mg ml  1.
Olipudase alfa was puriﬁed from culture media using hydrophobic interaction
chromatography followed by ion exchange chromatography. Eluate was
concentrated and subjected to gel-ﬁltration as described in puriﬁcation of ASM
from HEK293S Gnt1  cells. The monomer peak was eluted 0.9 ml earlier than
ASM from HEK293 S Gnt1  cells (Supplementary Fig. 6). Peak fractions were
collected and concentrated to 20 mg ml  1 for crystallization.
Crystallization. ASM was crystallized with in situ proteolysis of endoproteinase
Glu-C at 1:200 protease:ASM mass ratio. Crystals were obtained in sitting drops at
21 °C using a well solution of 1.5 M ammonium sulfate, 0.1 M sodium acetate pH
5.0–5.5, 12 % glycerol. Olipudase alfa crystals were obtained at 21 °C in the same
condition, but without any protease in the drops.
Platinum derivatives were prepared by soaking native crystals in well solution
supplemented with 10 mM K2PtCl4 for 10 min at 21 °C. Derivatized crystals were

NATURE COMMUNICATIONS | 7:13082 | DOI: 10.1038/ncomms13082 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13082

back soaked for 5 min in a cryo protectant solution supplemented with 20%
glycerol and ﬂash frozen in liquid nitrogen.
The phosphocholine bound crystals were generated by soaking native crystals in
well solution supplemented with 30 mM phosphocholine for 15 min at 21 °C.
Crystals were collected as with Pt-derivatives.
Data collection. X-ray ﬂuorescence scans identiﬁed zinc in crystals. SAD data
were collected at beamline SER-CAT 22ID at the Advanced Photon Source
(APS, USA). Diffraction from native crystals was collected at the Zn peak
wavelength (1.2830 Å) and Pt-derivatized crystals at the Pt L-III edge (1.0721 Å).
Phosphocholine-soaked data were collected on a Rigaku FR-E þ X-ray generator
with a Cu anode and Saturn 944 þ CCD detector. Zn and Pt SAD data were
processed with HKL2000 (ref. 34), and phosphocholine data were processed with
iMosﬂm and Scala35,36. Diffraction of olipudase alfa was performed at the Zn peak
wavelength (1.2825 Å) at beamline CMCF-08ID at the Canadian light source, and
the SAD data were processed with XDS37,38. Data collection statistics are listed in
Table 1.
Structure determination. Pt-SAD data were used in phenix.autosol for Pt location
search, phasing and density modiﬁcation39. Six Pt sites were found (Supplementary
Fig. 4a), and the ﬁgure of merit for phasing was 0.251. The density-modiﬁed map
was loaded into buccaneer in CCP4 for protein-chain building40. Over 90% of the
ASM residues were traced.
The holo ASM structure was completed using the higher-resolution Zn-SAD
data. The output model from Pt-SAD was put into phaser MR-SAD41 against the
Zn-SAD data for Zn searching and phasing. Two zinc atoms were located in each
protein monomer (Supplementary Fig. 4b). The model was reﬁned against
anomalous amplitudes with phenix.reﬁne42, and Hendrickson–Lattman coefﬁcients
from phaser MR-SAD were applied during reﬁnement. Model building was
completed with Coot43. The sequence-to-structure register was guided by the
glycosylation sites and disulﬁde bonds. Continuous electron density was observed
from W84 to M611, and all main chain atoms are visible in the electron density.
The holo structure was used as a search model for MR phasing of
phosphocholine data with phaser. One phosphocholine was built into the Fo-Fc
difference map with Coot (Supplementary Fig. 4c), and reﬁnement was completed
with phenix.reﬁne.
Structure determination and reﬁnement of olipudase alfa were the same as
described for holo ASM. Three protein monomers were found in each asymmetric
unit. NCS restraints were applied, and high resolution ASM holoenzyme structure
was used as reference structure during the reﬁnement with phenix.reﬁne. Two zinc
atoms were located in each monomer according to the anomalous difference map
(Supplementary Fig. 2b). Glycosylations on N175, N335, N503 and N520 were
clearly visible in omit Fo-Fc maps (Supplementary Fig. 2a). Residues W84 to M611
were built into the electron density.
The ﬁnal statistics for model building and reﬁnement are listed in Table 1.
Figures of structures are generated with PyMOL44.
Docking sphingomyelin to ASM. To better visualize how the hydrocarbon
chains might be placed on ASM upon substrate binding, a carbon-16 (C-16)
sphingomyelin was docked to holo ASM with MOE 2014 (ref. 45). Amber10: EHT
force ﬁeld and R-ﬁeld solvation were used. The ASM structure was prepared for
3D protonation with default parameters except that histidine, asparagine and
glutamine side-chain conformations were retained. Sphingomyelin and ASM were
energy minimized with default parameters. Phosphocholine interacting residues
and zinc ions were selected as dock sites. In addition, I134, F138, and M142 in the
saposin H3 helix were also included as dock sites based on the published saposin B
and lipid crystal structure16. Phosphocholine was selected as ligand template, and
template similarity placement protocol and induced ﬁt protocol were applied in the
docking procedure. Duplicated poses were removed and 30 energy favoured poses
were retained after two rounds of rescoring. Other parameters were set as default.
This docking is limited by the lack of computational restraints on two nearby zinc
ions and numerous rotatable bonds in sphingomyelin. The wide open substrate
binding cleft also contributed to the various conformations of hydrocarbon chains
in docked results. The output 30 poses of sphingomyelin were visually inspected
and validated based on whether the pose made reasonable interactions with ASM,
instead of only looking for the best energy favored position. Three poses were
selected and shown in Fig. 4.
Data availability. Coordinates and structure factors have been deposited in the
Protein Data Bank under accession code 5I81 (holo-ASM), 5I85 (ASM with
phosphocholine) and 5I8R (olipudase alfa).
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